The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial What we learn from subgroup analyses

被引：54
|
作者：
Ginsberg, Henry N. [1 ,2 ]
机构：
[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10027 USA
[2] Columbia Univ, Coll Phys & Surg, Irving Inst Clin & Translat Res, New York, NY USA
来源：
DIABETES CARE | 2011年 / 34卷
关键词：
CORONARY-HEART-DISEASE; LDL CHOLESTEROL; INTERVENTION; MEN; GEMFIBROZIL; PREVENTION; MORTALITY; THERAPY; PEOPLE;
D O I：
10.2337/dc11-s203
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S107 / S108
页数：2
相关论文
共 50 条
  • [1] Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Ginsberg, Henry N.
    Bonds, Denise E.
    Lovato, Laura C.
    Crouse, John R.
    Elam, Marshall B.
    Linz, Peter E.
    O'Connor, Patrick J.
    Leiter, Lawrence A.
    Weiss, Daniel
    Lipkin, Edward
    Fleg, Jerome L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A): : 56I - 67I
  • [2] Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods
    Buse, John B.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A): : 21I - 33I
  • [3] Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Kingry, Connie
    Bastien, Arnaud
    Booth, Gillian
    Geraci, Therese S.
    Kirpach, Brenda R.
    Ms, Lovato
    Margolis, Karen L.
    Sperl-Hillen, JoAnne M.
    Vargo, Laura
    Williamson, Jeff D.
    Probstfield, Jeffrey L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A): : 68I - 79I
  • [4] Glycemia treatment strategies in the action to control cardiovascular risk in diabetes (ACCORD) trial
    Gerstein, Hertzel C.
    Riddle, Matthew C.
    Kendall, David M.
    Cohen, Robert M.
    Goland, Robin
    Feinglos-, Mark N.
    Kirk, Julienne K.
    Hamilton, Bruce P.
    Ismail-Beigi, Faramarz
    Feeney, Patricia
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A): : 34I - 43I
  • [5] Lipid variability and risk of microvascular complications in Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: A post hoc analysis
    Hukportie, Daniel Nyarko
    Li, Fu-Rong
    Zhou, Rui
    Zheng, Jia-Zhen
    Wu, Xiao-Xiang
    Zou, Meng-Chen
    Wu, Xian-Bo
    JOURNAL OF DIABETES, 2022, 14 (06) : 365 - 376
  • [6] Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial-Clinical Implications
    Ismail-Beigi, Faramarz
    CLINICAL CHEMISTRY, 2011, 57 (02) : 261 - 263
  • [7] Rationale design, and methods of the action to control cardiovascular - Risk in diabetes (Accord) trial - Introduction
    Byington, Robert P.
    Genuth, Saul
    Friedewald, William T.
    Simons-Morton, Denise G.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A): : 1I - 3I
  • [8] Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics The Action to Control The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Calles-Escandon, Jorge
    Lovato, Laura C.
    Simons-Morton, Denise G.
    Kendall, David M.
    Pop-Busui, Rodica
    Cohen, Robert M.
    Bonds, Denise E.
    Fonseca, Vivian A.
    Ismail-Beigi, Faramarz
    Banerji, Mary Ann
    Failor, Alan
    Hamilton, Bruce
    DIABETES CARE, 2010, 33 (04) : 721 - 727
  • [9] Cardiac Autonomic Dysfunction Prodicts Cardiovascular Mortality in the Action To Control Cardiovascular Risk in Diabetes (ACCORD) Trial
    Pop-Busui, Rodica
    Evans, Gregory
    Gerstein, Hertzel C.
    Fonseca, Vivian
    Genuth, Saul
    Fleg, Jerome
    Corson, Marshall
    Grimm, Richard
    Prineas, Ronald
    DIABETES, 2009, 58 : A63 - A63
  • [10] Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
    Tonkin, Andrew M.
    Chen, Lei
    CIRCULATION, 2010, 122 (08) : 850 - 852
12345